Perspective announces information on Celsium-131 to be presented at ABS

Perspective Therapeutics announced that the growing body of information regarding Cesium-131 brachytherapy in the treatment of prostate cancer will be highlighted in two presentations at the 2023 American Brachytherapy Society, ABS, Annual Meeting to be held in Vancouver, British Columbia, Canada from June 21-24, 2023. “We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer. He added, “We’re also excited to note that the American Brachytherapy Society is including a session entitled, ‘Implementation of Radiopharmaceuticals in the Radiation Oncology Clinic’. With our focus on alpha-particle radiopharmaceuticals and Cesium-131 brachytherapy we’re closely aligned with ABS’s interests.” Presentation #1 Title: “Prostate Brachytherapy with Cs-131: Long Term Results Compared to Published SBRT Data.” The authors of presentation 1 noted that Cesium-131 LDR brachytherapy provided excellent disease-free survival rates at 5 and 10 years, comparable with recently published Stereotactic Body Radiation Therapy outcomes. It was noted that 47% of the brachytherapy patients had intermediate risk disease as compared to all low risk patients in the SBRT data. Presentation #2: Title: “All Isotopes Are Not Created Equal but Does One Stand Out?” Ryan P. Smith, MD will share his long term experience with Cesium-131.